Breaking News, Collaborations & Alliances

Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement

Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications.

By: Rachel Klemovitch

Assistant Editor

Jazz Pharmaceuticals plc and Saniona have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355. SAN2355 is a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications, designed to overcome the limitations of non-selective Kv7-targeting compounds.  Jazz will lead and fund further development, regulatory submissions, and global commercialization activities. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters